CFO about CLS’ aims

1 March, 2023

CFO about CLS’ aims

1 March, 2023

The reporting season for the fourth quarter of 2022 is coming to an end, and last week medtech company Clinical Laserthermia Systems published its report. The company’s CFO Rolf Bornschein visited BioStock’s studio to summarise Q4 and tell us more about CLS’s aims.

See the interview with CLS CFO Rolf Bornschein below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev

RELATED ARTICLESMORE FROM AUTHOR

CLS predicts continued growth in 2025–2026

CLS’ partner initiates full market release in the US

CLS revises strategy – increases focus on neurosurgery

RELATED ARTICLES MORE FROM AUTHOR